IL-22 has recently been proposed as a target for cancer therapy [9] as its increased expression has been reported in colonic [39], gastric [20], and hepatocellular cancer [19], as well as in small- and large-cell lung carcinoma [40]. Here, IL22 is linked to hepatocellular carcinoma.